Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

15 results about "Spleen Tissue" patented technology

The spleen is the largest lymphatic organ in the body. Surrounded by a connective tissue capsule, which extends inward to divide the organ into lobules, the spleen consists of two types of tissue called white pulp and red pulp. The white pulp is lymphatic tissue consisting mainly of lymphocytes around arteries.

Use of Ejiao Qianggu Oral Liquid in Regulating Immunity

ActiveCN118267430BDispersion deliveryImmunological disordersWhite blood cellColony-stimulating factor
The application discloses a use of Ejiao Qianggu oral liquid in regulating immunity, and particularly relates to an improving effect of the Ejiao Qianggu oral liquid on an immune system, which is realized by the following aspects. On one hand, the Ejiao Qianggu oral liquid promotes proliferation and transformation (mainly early T lymphocytes and part of B lymphocytes) and active functions of spleen lymphocytes; on the other hand, the Ejiao Qianggu oral liquid improves phagocytosis of macrophages. The Ejiao Qianggu oral liquid has the following characteristics: firstly, the Ejiao Qianggu oral liquid acts on early lymphocyte maturation, and has no significant effect on proliferation of peripheral blood lymphocytes; secondly, the Ejiao Qianggu oral liquid can significantly act on immune target organs, thymus and spleen tissues, and does not excessively stimulate the spleen, unlike positive drugs such as colony stimulating factor which can cause significant edema of the spleen; and thirdly, the Ejiao Qianggu oral liquid has a significant recovery effect on body weight, white blood cells, lymphocytes, red blood cells and hemoglobin in blood of patients with low immunity.
Owner:XINJIANG HUASHIDAN PHARMA +1

Lipid nanoparticles for delivering nucleic acid to splenic tissue, and method for delivering nucleic acid to splenic tissue using same

The present invention provides lipid nanoparticles for delivering nucleic acid to spleen tissue that can improve the efficiency of nucleic acid delivery to spleen tissue cells, and a method for delivering nucleic acid to spleen tissue by using same. A lipid nanoparticle for use in delivering a nucleic acid to a spleen tissue, including(A) an ionic lipid represented by the formula (1),(B) an anionic phospholipid or a compound represented by the formula (2),(C) cholesterol, and(D) a dimyristoylglycerol PEG represented by the formula:(definitions of symbols in the formula are as described in the specification), and a method for delivering a nucleic acid to a spleen tissue by using same.
Owner:CHIBA UNIV +2

Bioactive heptadecapeptide and use thereof

The present application provides a kind of bioactive seventeen peptides and its application, belong to bioactive peptide technical field, the amino acid sequence of the seventeen peptides is as shown in SEQ ID NO.1;Seventeen peptides provided by the present application can significantly reduce immune damage, improve immune organ index, reduce spleen tissue damage, can significantly promote the secretion level of immunoglobulin and cytokine in blood;The polypeptide has immunoregulation, can improve immunity, can be used for preparing the product of enhancing immunity.
Owner:QILU UNIVERSITY OF TECHNOLOGY (SHANDONG ACADEMY OF SCIENCES)

A prmt5 inhibitor and its use in improving primary biliary cholangitis

PendingCN122440828ANucleotideSerum autoantibodies
The present application provides a kind of PRMT5 inhibitor, PRMT5 inhibitor includes: recombinant adeno-associated virus vector AAV-shPrmt5 and GSK3326595;Recombinant adeno-associated virus vector AAV-shPrmt5 includes the shRNA of targeting PRMT5, the nucleotide sequence of shRNA is as shown in SEQ ID No:1.The present application also provides the application of the above-mentioned PRMT5 inhibitor in the preparation of drug for improving primary biliary cholangitis, PRMT5 inhibitor is all PRMT5 gene / protein as target point, by inhibiting the expression of PRMT5 gene / protein, reduce liver tissue and spleen tissue Tfh cell and GC B cell, serum autoantibody and transaminase level, can effectively delay the disease progression of primary biliary cholangitis.
Owner:CHANGSHU NO 2 PEOPLES HOSPITAL

Application of glucuronolactone in the preparation of feed to alleviate spleen damage caused by combined PRRSV and vomitoxin

This invention belongs to the field of animal feed technology and discloses the application of glucuronolactone in the preparation of feed that alleviates spleen damage caused by the combined effects of PRRSV and DON. This invention discovers that glucuronolactone can effectively alleviate spleen damage in piglets caused by co-exposure to PRRSV and DON. It exerts its protective effect by activating the Nrf2 antioxidant signaling pathway, improving spleen tissue structure, alleviating oxidative stress, inhibiting inflammatory responses, and inhibiting apoptosis. This invention also provides a feed containing the aforementioned effective amount of glucuronolactone, with the basic feed tailored to the nutritional needs of piglets. This invention fills the technological gap in effective intervention methods for spleen damage under PRRSV and DON co-exposure. The glucuronolactone addition process is simple, the effect is significant, and it is suitable for large-scale feed production. It can effectively solve the problem of immunosuppression in pig herds caused by the combined harm of PRRSV and DON in the pig industry, and has important practical value.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY

A traditional Chinese medicine composition, a preparation method therefor and application thereof

The present application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition, a preparation method and application thereof. Specifically, based on the theory of traditional Chinese veterinary medicine of'strengthening the body resistance and eliminating pathogenic factors, and treating the root and branch', aiming at the pathogenesis of 'deficiency in the root and excess in the branch' of low immunity in animals, eight kinds of medicinal materials are scientifically screened to form a traditional Chinese medicine compound with the effects of tonifying qi and nourishing blood, invigorating the spleen and kidney, dredging collaterals and eliminating dampness, and clearing heat and detoxifying. Through the verification of a cyclophosphamide-induced low immunity mouse model, the traditional Chinese medicine composition can significantly improve the mental state of the mice, restore the body weight and thymus / spleen index, repair the pathological damage of the spleen tissue, and adjust the inflammatory factor level in the serum and spleen tissue. In addition, in a Marek's disease virus infection model, the traditional Chinese medicine composition combined with the Marek's disease virus vaccine can significantly reduce the viral load in the peripheral blood, liver and spleen, and reduce the liver enlargement, hemorrhage and microscopic structure damage, showing a good immune synergistic effect.
Owner:HUNAN VOCATIONAL COLLEGE OF SCI & TECH +2

Preparation method of spleen extract

The invention relates to the technical field of polypeptide preparation, and discloses a spleen extract preparation method, which comprises: carrying out pretreatment, homogenization, freeze thawing crushing, precipitation separation and ultrafiltration on a mammal spleen tissue to obtain a spleen polypeptide extract; coupling the spleen polypeptide extract with ADC through a chemical coupling bridge to form a targeting compound; preparing an antioxidant-basic amino acid compound; mixing the coupling compound with a wall material solution containing a functional filling agent and an antioxidant-alkaline amino acid compound, and carrying out microencapsulation embedding; carrying out freeze drying on the microcapsules; and spraying a chitosan-sodium carboxymethyl cellulose polyelectrolyte compound on the surface of the freeze-dried microcapsule to carry out hydrophilic modification. The antioxidant-basic amino acid compound is used for blocking intermolecular chemical crosslinking, the cyclodextrin inclusion effect is used for preventing aggregation, and the polysaccharide composite hydrophilic layer is used for providing environmental tolerance, so that the chemical crosslinking rate of the product is reduced by 80% or above, and the aggregation rate is reduced to 5% or below.
Owner:JILIN FENGSHENG PHARM CO LTD

Application of xanthoceras sorbifolia extract in preparation of medicine for preventing and / or treating electromagnetic radiation damage

The invention discloses application of a xanthoceras sorbifolia extract in preparation of a medicine for preventing and / or treating electromagnetic radiation damage. Experiments show that the xanthoceras sorbifolia bunge flower extract can improve the weight loss of rats caused by microwave radiation; brain tissue structure change damage caused by microwave radiation is improved; the reduction of the learning and memory ability of the rats caused by microwave radiation is improved; the brain sea horse tissue amino acid neurotransmitter disorder caused by microwave radiation is improved; electroencephalogram alpha and beta wave abnormity caused by microwave radiation is improved; the sperm motility reduction caused by microwave radiation is improved; the rat serum sex hormone disorder caused by microwave radiation is improved; rat testicular tissue oxidative stress injury caused by microwave radiation is improved; the abnormal energy metabolism of testicular tissues caused by microwave radiation is improved; heart electrophysiological abnormality and heart tissue ultrastructure abnormality caused by microwave radiation are improved; the immune function decline caused by microwave radiation is improved; the influence of microwave radiation on the content of IL-2, 4 is improved; the influence of microwave radiation on the thymus and spleen tissue structure is improved.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES +1

Spleen structure analysis method and device, electronic equipment and storage medium

PendingCN122417138AData setStructure analysis
Embodiments of the present application provide a spleen structure analysis method and device, electronic equipment and storage medium. The method comprises obtaining a spleen structure analysis request, the spleen structure analysis request comprising first single-cell sequencing data and first spatial transcriptome sequencing data of a spleen tissue to be analyzed; determining a plurality of first significantly expressed gene data corresponding to a plurality of cell types according to the first single-cell sequencing data, and determining a plurality of second significantly expressed gene data corresponding to a plurality of spleen partitions according to the first spatial transcriptome sequencing data; determining a first intersection between the second significantly expressed gene data of each spleen partition and the first significantly expressed gene data of each cell type, and constructing an input data set based on the first intersection; determining a spleen structure analysis result according to the similarity between the input data set and a reference data set, the reference data set being a data set corresponding to a spleen sample of a reference spleen structure. The method can improve the accuracy of spleen structure analysis.
Owner:SHENZHEN HUADA GENE INST +1

Novel pediococcus acidilactici strain having immunity-enhancing efficacy and composition for enhancing immunity, comprising same

The present invention relates to a novel Pediococcus acidilactici WiKim0170 strain having immunity-enhancing efficacy and a composition for enhancing immunity, comprising same. In the present invention, it has been discovered that the Pediococcus acidilactici WiKim0170 strain, which is a novel strain derived from makgeolli, significantly increases spleen NK cell activity and increases inflammatory mediator, immunoglobulin, and cytokine production amounts, thereby improving an immunosuppressive reaction. In addition, the Pediococcus acidilactici WiKim0170 strain has been confirmed to increase the mRNA expression levels of iNOS, COX2, TNF-α, IL-1β, IL-6, IL-2, IL-12, and IL-10 in spleen tissue and increase the phosphorylation levels of NF-κB and IκBα, thereby having an effect of mitigating decreased immunity. Thus, according to the present invention, the composition comprising the Pediococcus acidilactici WiKim0170 strain, which is a novel strain derived from makgeolli, as an active ingredient is expected to be usefully employable as a pharmaceutical and functional food composition for enhancing immunity.
Owner:PHARMSVILLE

Application of Harman alkali in preparation of Pseudomonas plecoglossicida inhibitor

The invention discloses an application of Harman alkali in the aspect of preparing a Pseudomonas plecoglossicida inhibitor, and is characterized in that the Harman alkali is applied in the aspect of preparing a medicine for preventing and / or treating aquatic animal infectious diseases caused by Pseudomonas plecoglossicida. The invention further provides application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating aquatic animal plecoglossus altivelis pseudomonas infection, application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating plecoglossus altivelis liver injury, application of a plecoglossus altivelis immunoregulation medicine and application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of an aquaculture feed additive. The method has the advantages that the survival rate of aquatic animals can be remarkably increased in a Pseudomonas plecoglossicida infection model, the bacterial load in immune tissues such as blood, liver, spleen, head and kidney and the like is reduced, and liver and spleen tissue pathological injury and cell apoptosis caused by infection are relieved; meanwhile, harmine can improve biochemical and antioxidant indexes of infection-related serum, and has no obvious toxicity to fish-derived cells within a certain concentration range.
Owner:NINGBO UNIV

Antibody-exosome, preparation method thereof and application of antibody-exosome in preparation of ricin detoxification medicine

The invention provides an antibody-exosome, a preparation method thereof and application of the antibody-exosome in preparation of ricin detoxification drugs, and belongs to the technical field of drug delivery and intracellular therapy. The antibody-exosome disclosed by the invention comprises a milk-derived exosome (mExo) and a single-domain antibody V9E1 of an anti-ricin A chain; the amino acid sequence of the V9E1 is as shown in SEQ ID NO. 1. V9E1 is loaded into a milk exosome by using a saponin perforation method to obtain a V9E1 antibody-exosome, and the antibody-exosome shows reliable biological safety in both cells and animal bodies; the cell survival rate can be obviously improved in a Vero cell acute poisoning model; after mice are poisoned by ricin for 2 hours and 6 hours, the survival rate of the mice can be remarkably improved; through continuous administration, all mice injected with ricin with a complete lethal dose can survive, liver and spleen tissues can be protected, and the method has the potential of replacing a traditional ricin antibody therapy.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

A lipid compound and its application

This invention provides a lipid compound and its applications, the results of which are shown in Formula I. The lipid compound provided by this invention can be used for targeted delivery of bioactive molecules to splenic T cells, particularly suitable for transporting negatively charged nucleic acid molecules, such as mRNA, providing a potential delivery strategy for in vivo specific gene editing of T cells. This invention also provides a bioactive substance delivery system comprising the lipid compound, which is loaded with bioactive substances. The bioactive substance delivery system of this invention, after intravenous administration, can efficiently target spleen tissue and selectively deliver active substances to T cells within the spleen, achieving efficient T cell transfection and immune activation. The delivery system of this invention has a simple synthesis process and strong structural tunability, and has broad application prospects in the fields of T cell immunotherapy and gene therapy.
Owner:THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA

A spleen polypeptide extract, a preparation method and application thereof

The application relates to the technical field of biological extraction, and discloses a spleen polypeptide extract as well as a preparation method and application thereof. The preparation method takes fresh spleen tissue as raw material, and realizes preliminary separation of proteins, polypeptides and nucleic acids through an optimized isoelectric point grading process after pretreatment, homogenization, repeated freeze-thaw crushing, centrifugal separation and ultrafiltration grading, and finally obtains high-content products by adopting targeted chromatography purification technology. The spleen polypeptide extract and related products can be widely applied to the fields of biological medicines (such as immunomodulators and blood substitutes), food additives (such as protein fortifiers) and scientific reagent fields, the process is mild and has good repeatability, the comprehensive utilization of the spleen raw material is realized, the product added value is improved, and the application prospect of industrialization is good.
Owner:JILIN FENGSHENG PHARM CO LTD

Cationic lipid compositions for tissue-specific delivery

Provided herein are, inter alia, compositions and methods useful for the in vivo delivery of bioactive agents (e.g., therapeutic or diagnostic agents). The compositions provided herein include cationic lipids, helper lipids and a biostability enhancing agent, which together form a lipid aggregate with the bioactive agent and allow for the systemic delivery of the bioactive agent to, for example, spleen tissue without the requirement for biomolecular targeting.
Owner:LIFE TECHNOLOGIES CORP